Compound Reference Overview
| Field | Value |
|---|---|
| Name | TB-500 (Thymosin Beta-4) |
| Reference Code | TB-500 |
| Category | Healing & Recovery Peptide |
| Example Strengths | 5 mg, 10 mg vial (varies by formulation) |
| Reference Range | 2–2.5 mg twice weekly (loading); 2–2.5 mg weekly (maintenance) |
| Frequency | Loading: twice weekly; Maintenance: once weekly |
| Key Safety Warning | Not FDA-approved. Listed on WADA prohibited substances list. Avoid in active malignancy due to theoretical cell proliferation concerns. Systemic effect regardless of injection site. |
Mechanism of Action (Educational)
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide involved in tissue repair and regeneration.
Preclinical data suggest it promotes cell migration, angiogenesis, actin regulation, and anti-inflammatory signaling.
Its effects are considered systemic, meaning local injection site does not limit biologic activity.
Indications (Investigational)
- Soft tissue injury research
- Tendon and ligament repair investigations
- Muscle recovery studies
- Hair regrowth research (limited data)
Administration (Investigational Protocols)
| Parameter | Details |
|---|---|
| Route | Subcutaneous |
| Frequency | Loading phase: 2x weekly; Maintenance phase: weekly |
| Injection Site | Abdomen (systemic effect regardless of site) |
| Timing | Any time of day |
Pharmacokinetics (Limited Human Data)
Estimated biologic activity persists for approximately ~2 weeks.
Preclinical healing effects are typically observed within 1–2 weeks of loading. Comprehensive human pharmacokinetic data remain limited.
Titration Schedule (Investigational Example)
- Weeks 1–6: 2–2.5 mg twice weekly (loading phase)
- Week 7+: 2–2.5 mg once weekly (maintenance phase)
Higher loading protocols (up to 5 mg twice weekly) have been described in some investigational settings.
Reconstitution & Concentration (Mathematical Standardization Model)
For educational standardization purposes, concentration may be normalized so that 0.10 mL (10 insulin units) = 500 mcg when reconstituting a 10 mg vial with 2 mL diluent.
| Parameter | Value |
|---|---|
| Diluent | Bacteriostatic water |
| Example Reconstitution (10 mg vial) | 10 mg + 2 mL diluent |
| Resulting Concentration | 5 mg/mL (5000 mcg/mL) |
| Stability | Up to 28 days refrigerated (2–8°C; varies by formulation) |
Conversion Reference
- 10 units = 500 mcg
- 20 units = 1 mg
- 50 units = 2.5 mg
This section is provided strictly for arithmetic illustration and does not constitute dosing guidance.
Safety & Contraindications (Summary)
Contraindications
- Active malignancy (theoretical cell proliferation risk)
- Pregnancy or breastfeeding
- Active systemic infections
Drug Interactions
- BPC-157: Often described as synergistic in healing-focused protocols
Adverse Events
- Injection site reactions
- Temporary lethargy
- Head rush sensation
Serious Risks
- Theoretical cancer risk (based on proliferative signaling mechanisms)
Monitoring (Investigational)
- Injury healing progression
- General wellbeing
- Fluid balance and tolerance
Mathematical Calculation Tool
The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
Disclaimer
TB-500 (Thymosin Beta-4) is not FDA-approved for therapeutic use. Available data are primarily preclinical with limited controlled human studies. This content is provided strictly for educational and professional reference purposes.
Reference Sources
1. Goldstein AL, et al. Thymosin beta-4: Biology and therapeutic potential.
Ann N Y Acad Sci. 2004; PMID: 15217986.
2. Malinda KM, et al. Thymosin beta-4 promotes angiogenesis and tissue repair.
FASEB J. 2006; PMID: 16887101.
3. Smart N, et al. Thymosin beta-4 and tissue regeneration.
Nat Rev Cardiol. 2011; PMID: 21866268.